AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) shares traded down 2.4% during trading on Thursday . The stock traded as low as $3.24 and last traded at $3.25, with a volume of 93,903 shares traded. The stock had previously closed at $3.33.

Several research analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective (down previously from $9.00) on shares of AcelRx Pharmaceuticals in a research note on Tuesday, May 3rd. Cowen and Company reissued a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Monday, May 2nd. Seaport Global Securities raised AcelRx Pharmaceuticals from an “accumulate” rating to a “buy” rating in a research note on Friday, May 6th. RBC Capital Markets reissued a “positive” rating and set a $6.00 target price on shares of AcelRx Pharmaceuticals in a research note on Tuesday, August 16th. Finally, Stifel Nicolaus downgraded AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. AcelRx Pharmaceuticals currently has an average rating of “Hold” and an average target price of $7.30.

The stock’s market capitalization is $145.45 million. The firm’s 50-day moving average is $3.31 and its 200-day moving average is $3.34.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings results on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by $0.02. The business earned $4.53 million during the quarter, compared to analyst estimates of $2.17 million. On average, equities analysts expect that AcelRx Pharmaceuticals Inc. will post ($0.91) earnings per share for the current fiscal year.

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.